Sanara MedTech initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Sanara MedTech (SMTI) with a Buy rating and $50 price target The medical technology company is focused on the development and commercialization of products and services that improve clinical outcome in the surgical and chronic wound care markets and the company’s successful strategy of market penetration and geographic expansion could continue to drive topline growth in the coming quarters, the analyst tells investors. The company’s lead product is CellerateRX Surgical, which is indicated for the management of surgical, traumatic, and partial- and full-thickness wounds as well as first- and second-degree burns, the analyst noted.